- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Senores Pharmaceuticals' board met, approving strong Q1 FY26 consolidated financial results. Total Income surged 72% YoY to Rs 138.0 Cr. EBITDA jumped 60% YoY to Rs 34.2 Cr, while Profit After Tax (PAT) nearly doubled, rising 95% YoY to Rs 21.2 Cr. The company also announced the appointment of Mr. Jignesh Shashikant Desai as President-Finance, bringing over 30 years of experience to the Senior Management team. This signals solid operational performance and a key strategic hire.